USD 3.57
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| AGEN | -5.1 | 10.5 | 29.8 | -19.0 | -41.8 | -69.6 | -93.4 | -95.3 | -96.6 | -100.0 |
| S&P 500 | -0.3 | 1.8 | 1.0 | 5.0 | 12.4 | 25.3 | 38.3 | 85.1 | 196.6 | 34448.4 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | AGEN |
| name | Agenus Inc. |
| price | 3.57 |
| changes percentage | -5.0532 |
| change | -0.19 |
| day low | 3.55 |
| day high | 3.951 |
| year high | 19.69 |
| year low | 2.5 |
| market cap | 83748273 |
| price avg 50 | 3.173 |
| price avg 200 | 7.3578 |
| exchange | NASDAQ |
| volume | 372102 |
| avg volume | 534423 |
| open | 3.73 |
| previous close | 3.76 |
| eps | -11.02 |
| pe | -0.32 |
| earnings announcement | 2025-03-12T12:30:00.000+0000 |
| shares outstanding | 23458900 |
| timestamp | 2025-01-24 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001098972 | |||
| revenue | 156314000 | 98024000 | 59.47 |
| gross profit | -81366000 | -99235000 | 18.01 |
| gross profit ratio | -0.52 | -1.01 | 48.58 |
| research and development expenses | 234569000 | 16975000 | 1281.85 |
| operating expenses | 78183000 | 81007000 | -3.49 |
| interest income | 0 | 61863000 | -100.00 |
| interest expense | 97925000 | 61863000 | 58.29 |
| ebitda | -145924000 | -161847000 | 9.84 |
| ebitdaratio | -0.93 | -1.64 | 43.07 |
| operating income | -159549000 | -179427000 | 11.08 |
| operating income ratio | -1.02 | -1.83 | 44.24 |
| net income | -245761000 | -271515000 | 9.49 |
| net income ratio | -1.57 | -2.77 | 43.24 |
| eps | -13.75 | -19.27 | 28.65 |
Revenue Growth: revenue decreased to 156 million in 2023 from 98 million in 2022 representing a change of 59.47%. This indicates a sales shrinking, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -146 million in 2023 from -162 million in 2022 representing a change of 9.84%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -160 million in 2023 from -179 million in 2022 representing a change of 11.08%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -246 million in 2023 from -272 million in 2022 representing a change of 9.49%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Gross Profit: Gross Profit increased to -81 million in 2023 from -99 million in 2022 representing a change of 18.01%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 235 million in 2023 from 17 million in 2022 representing a change of 1281.85%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 78 million in 2023 from 81 million in 2022 representing a change of -3.49%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -13.75 in 2023 from -13.75 in 2022 representing a change of 28.65%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001098972 | |||
| revenue | 25112000 | 23509000 | 6.82 |
| gross profit | -16092000 | 23394000 | -168.79 |
| gross profit ratio | -0.64 | 1.0 | -164.40 |
| research and development expenses | 41058000 | 36771000 | 11.66 |
| operating expenses | 15412000 | 16816000 | -8.35 |
| interest income | 0 | 0 | NaN |
| interest expense | 35729000 | 31745000 | 12.55 |
| ebitda | -28139000 | -19689000 | -42.92 |
| ebitdaratio | -1.12 | -0.84 | -33.79 |
| operating income | -31504000 | -30193000 | -4.34 |
| operating income ratio | -1.25 | -1.28 | 2.32 |
| net income | -66386000 | -53081000 | -25.07 |
| net income ratio | -2.64 | -2.26 | -17.08 |
| eps | -3.08 | -2.52 | -22.22 |
Revenue Growth: revenue increased to 25 million in 2024Q3 from 24 million in 2024Q2 representing a change of 6.82%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 41 million in 2024Q3 from 37 million in 2024Q2 representing a change of 11.66%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 15 million in 2024Q3 from 17 million in 2024Q2 representing a change of -8.35%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -28 million in 2024Q3 from -20 million in 2024Q2 representing a change of -42.92%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -32 million in 2024Q3 from -30 million in 2024Q2 representing a change of -4.34%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -66 million in 2024Q3 from -53 million in 2024Q2 representing a change of -25.07%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Gross Profit: Gross Profit decreased to -16 million in 2024Q3 from 23 million in 2024Q2 representing a change of -168.79%. This indicates a sales profitability decline, which is a negative sign for the company.
Earnings per Share (EPS): EPS increased to -3.08 in 2024Q3 from -3.08 in 2024Q2 representing a change of -22.22%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001098972 | |||
| total assets | 313913000 | 413556000 | -24.09 |
| total liabilities | 462295000 | 468458000 | -1.32 |
| total equity | -148382000 | -54902000 | -170.27 |
| cash and cash equivalents | 76110000 | 178674000 | -57.40 |
| short term investments | 447000 | 14684000 | -96.96 |
| long term investments | 3222000 | 2669000 | 20.72 |
| total current assets | 112416000 | 213122000 | -47.25 |
| total non current assets | 201497000 | 200434000 | 0.53 |
| total current liabilities | 255897000 | 188952000 | 35.43 |
| total non current liabilities | 206398000 | 279506000 | -26.16 |
| common stock | 3944000 | 3056000 | 29.06 |
| retained earnings | -1955668000 | -1709907000 | -14.37 |
| total debt | 78012000 | 78428000 | -0.53 |
Total Assets: Total Assets decreased to 314 million in 2023 from 414 million in 2022 representing a change of -24.09%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to -148 million in 2023 from -55 million in 2022 representing a change of -170.27%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 76 million in 2023 from 179 million in 2022 representing a change of -57.4%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2023 from 15 million in 2022 representing a change of -96.96%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 112 million in 2023 from 213 million in 2022 representing a change of -47.25%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 256 million in 2023 from 189 million in 2022 representing a change of 35.43%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,956 million in 2023 from -1,710 million in 2022 representing a change of -14.37%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 462 million in 2023 from 468 million in 2022 representing a change of -1.32%. This indicates a decrease in overall liabilities.
Common Stock: Common Stock increased to 4 in 2023 from 3 in 2022 representing a change of 29.06%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 78 million in 2023 from 78 million in 2022 representing a change of -0.53%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001098972 | |||
| total assets | 238482000 | 292415000 | -18.44 |
| total liabilities | 510286000 | 513254000 | -0.58 |
| total equity | -66794000 | -220839000 | 69.75 |
| cash and cash equivalents | 44784000 | 93723000 | -52.22 |
| short term investments | 0 | 2141000 | -100.00 |
| long term investments | 0 | 1493000 | -100.00 |
| total current assets | 50154000 | 100004000 | -49.85 |
| total non current assets | 188328000 | 192411000 | -2.12 |
| total current liabilities | 270644000 | 270666000 | -0.01 |
| total non current liabilities | 239642000 | 242588000 | -1.21 |
| common stock | 217000 | 211000 | 2.84 |
| retained earnings | -2137021000 | -2070635000 | -3.21 |
| total debt | 55164000 | 80874000 | -31.79 |
Total Assets: Total Assets decreased to 238 million in 2024Q3 from 292 million in 2024Q2 representing a change of -18.44%. Suggesting a decrease in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 45 million in 2024Q3 from 94 million in 2024Q2 representing a change of -52.22%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2024Q3 from 2 million in 2024Q2 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 50 million in 2024Q3 from 100 million in 2024Q2 representing a change of -49.85%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -2,137 million in 2024Q3 from -2,071 million in 2024Q2 representing a change of -3.21%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 510 million in 2024Q3 from 513 million in 2024Q2 representing a change of -0.58%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to -67 million in 2024Q3 from -221 million in 2024Q2 representing a change of 69.75%. This indicates an increase in shareholders' equity.
Total Current Liabilities: Total Current Liabilities decreased to 271 million in 2024Q3 from 271 million in 2024Q2 representing a change of -0.01%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 2.84%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 55 million in 2024Q3 from 81 million in 2024Q2 representing a change of -31.79%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001098972 | |||
| net change in cash | -101564000 | -113257000 | 10.32 |
| operating cash flow | -224202000 | -175373000 | -27.84 |
| free cash flow | -234156000 | -228435000 | -2.50 |
| capital expenditure | -9954000 | -53062000 | 81.24 |
| depreciation and amortization | 13588000 | 6946000 | 95.62 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 22869000 | 18337000 | 24.72 |
| accounts payables | 21366000 | 6494000 | 229.01 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -2917000 | 100.00 |
| investments in property plant and equipment | -9954000 | -53062000 | 81.24 |
| net cash used for investing activites | 3400000 | -33610000 | 110.12 |
| debt repayment | -8926000 | -490000 | -1721.63 |
| common stock issued | 133157000 | 99211000 | 34.22 |
| common stock repurchased | -4566000 | -3789000 | -20.51 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 119866000 | 95830000 | 25.08 |
| cash at end of period | 79779000 | 181343000 | -56.01 |
| accounts receivables | -23461000 | 122000 | -19330.33 |
| cash at beginning of period | 181343000 | 294600000 | -38.44 |
Net Change in Cash: Net Change in Cash increased to -102 million in 2023 from -113 million in 2022 representing a change of 10.32%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Accounts Receivables: Accounts Receivables decreased to -23 million in 2023 from 0 million in 2022 representing a change of -19330.33%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -224 million in 2023 from -175 million in 2022 representing a change of -27.84%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -234 million in 2023 from -228 million in 2022 representing a change of -2.5%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -10 million in 2023 from -53 million in 2022 representing a change of 81.24%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 23 million in 2023 from 18 million in 2022 representing a change of 24.72%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 21 million in 2023 from 6 million in 2022 representing a change of 229.01%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001098972 | |||
| operating cash flow | -53292000 | -38180000 | -39.58 |
| free cash flow | -52796000 | -38641000 | -36.63 |
| capital expenditure | 496000 | -461000 | 207.59 |
| depreciation and amortization | 3346000 | 3363000 | -0.51 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | -726000 | 4033000 | -118.00 |
| accounts receivables | 492000 | -220000 | 323.64 |
| accounts payables | -4964000 | 2015000 | -346.35 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 496000 | -461000 | 207.59 |
| net cash used for investing activites | 56000 | -237000 | 123.63 |
| debt repayment | -2660000 | -2592000 | -2.62 |
| common stock issued | 6776000 | 1990000 | 240.50 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 4557000 | 79083000 | -94.24 |
| net change in cash | -45305000 | 40867000 | -210.86 |
| cash at end of period | 48418000 | 93723000 | -48.34 |
| cash at beginning of period | 93723000 | 52856000 | 77.32 |
Net Change in Cash: Net Change in Cash decreased to -45 million in 2024Q3 from 41 million in 2024Q2 representing a change of -210.86%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -53 million in 2024Q3 from -38 million in 2024Q2 representing a change of -39.58%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -53 million in 2024Q3 from -39 million in 2024Q2 representing a change of -36.63%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 207.59%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 5 million in 2024Q3 from 2 million in 2024Q2 representing a change of -346.35%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q3 from 0 million in 2024Q2 representing a change of 323.64%. This suggests that the company is less capable of collecting payments from its customers.
Stock-Based Compensation: Stock-Based Compensation decreased to -1 million in 2024Q3 from 4 million in 2024Q2 representing a change of -118.0%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 8.74 | 6.96 | 25.54 |
| net income per share | -13.73 | -19.27 | 28.74 |
| operating cash flow per share | -12.53 | -12.45 | -0.64 |
| free cash flow per share | -13.09 | -16.22 | 19.30 |
| cash per share | 4.28 | 13.73 | -68.83 |
| book value per share | -8.29 | -3.9 | -112.76 |
| tangible book value per share | -9.92 | -6.15 | -61.38 |
| shareholders equity per share | -8.96 | -4.35 | -105.98 |
| interest debt per share | 9.83 | 9.96 | -1.27 |
| market cap | 296332092 | 676183200 | -56.18 |
| enterprise value | 298234092 | 575937200 | -48.22 |
| pe ratio | -1.21 | -2.49 | 51.58 |
| price to sales ratio | 1.9 | 6.9 | -72.52 |
| pocfratio | -1.32 | -3.86 | 65.72 |
| pfcf ratio | -1.27 | -2.96 | 57.25 |
| pb ratio | -1.85 | -11.03 | 83.25 |
| ptb ratio | -1.85 | -11.03 | 83.25 |
| ev to sales | 1.91 | 5.88 | -67.53 |
| enterprise value over ebitda | -2.04 | -3.56 | 42.57 |
| ev to operating cash flow | -1.33 | -3.28 | 59.50 |
| ev to free cash flow | -1.27 | -2.52 | 49.48 |
| earnings yield | -0.83 | -0.4 | -106.54 |
| free cash flow yield | -0.79 | -0.34 | -133.90 |
| debt to equity | -0.49 | -1.28 | 61.98 |
| debt to assets | 0.25 | 0.19 | 31.04 |
| net debt to ebitda | -0.01 | 0.62 | -102.10 |
| current ratio | 0.44 | 1.13 | -61.05 |
| interest coverage | -1.63 | -2.9 | 43.82 |
| income quality | 0.91 | 0.76 | 19.99 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.5 | 0.83 | -39.05 |
| research and ddevelopement to revenue | 1.5 | 0.17 | 766.55 |
| intangibles to total assets | 0.09 | 0.08 | 21.10 |
| capex to operating cash flow | -0.04 | -0.3 | 85.33 |
| capex to revenue | 0.06 | 0.54 | -88.24 |
| capex to depreciation | 0.73 | 7.64 | -90.41 |
| stock based compensation to revenue | 0.15 | 0.19 | -21.79 |
| graham number | 52.62 | 43.43 | 21.15 |
| roic | -2.63 | -0.93 | -182.42 |
| return on tangible assets | -0.86 | -0.71 | -21.37 |
| graham net net | -20.47 | -18.89 | -8.37 |
| working capital | -143481000 | 24170000 | -693.63 |
| tangible asset value | -177516000 | -86597000 | -104.99 |
| net current asset value | -349879000 | -255336000 | -37.03 |
| invested capital | 48680000 | 220151000 | -77.89 |
| average receivables | 14288500 | 2129500 | 570.98 |
| average payables | 51192500 | 35712500 | 43.35 |
| average inventory | 6914500 | 17095500 | -59.55 |
| days sales outstanding | 60.33 | 10.21 | 491.09 |
| days payables outstanding | 94.36 | 75.75 | 24.57 |
| days of inventory on hand | 0 | 25.59 | -100.00 |
| receivables turnover | 6.05 | 35.76 | -83.08 |
| payables turnover | 3.87 | 4.82 | -19.72 |
| inventory turnover | 0 | 14.26 | -100.00 |
| roe | 1.53 | 4.43 | -65.41 |
| capex per share | 0.56 | 3.77 | -85.23 |
ROE: Return on Equity (ROE) decreased to 1.53 on 2023-12-31 from 4.43 on 2022-12-31, representing a change of -65.41%. However, ROE is >= 15%, suggesting that the company has been generating high returns for its shareholders still.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to -0.49 on 2023-12-31 from -1.28 on 2022-12-31, representing a change of 61.98%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.21 on 2023-12-31 from -2.49 on 2022-12-31, representing a change of 51.58%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.44 on 2023-12-31 from 1.13 on 2022-12-31, representing a change of -61.05%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| AGEN | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 1.17 | 1.12 | 4.40 |
| net income per share | -3.08 | -2.52 | -22.23 |
| operating cash flow per share | -2.47 | -1.81 | -36.42 |
| free cash flow per share | -2.45 | -1.83 | -33.54 |
| cash per share | 2.08 | 4.55 | -54.34 |
| book value per share | -12.61 | -10.49 | -20.29 |
| tangible book value per share | -13.94 | -11.86 | -17.59 |
| shareholders equity per share | -4.05 | -11.46 | 64.63 |
| interest debt per share | 4.22 | 5.35 | -21.12 |
| market cap | 118094000.0 | 351524780 | -66.41 |
| enterprise value | 128474000.0 | 338675780 | -62.07 |
| pe ratio | -0.44 | -1.66 | 73.14 |
| price to sales ratio | 4.7 | 14.95 | -68.55 |
| pocfratio | -2.22 | -9.21 | 75.93 |
| pfcf ratio | -2.24 | -9.1 | 75.41 |
| pb ratio | -1.35 | -1.46 | 7.17 |
| ptb ratio | -1.35 | -1.46 | 7.17 |
| ev to sales | 5.12 | 14.41 | -64.49 |
| enterprise value over ebitda | -4.57 | -17.2 | 73.46 |
| ev to operating cash flow | -2.41 | -8.87 | 72.82 |
| ev to free cash flow | -2.43 | -8.76 | 72.24 |
| earnings yield | -0.56 | -0.15 | -272.28 |
| free cash flow yield | -0.45 | -0.11 | -306.71 |
| debt to equity | -0.63 | -0.34 | -88.49 |
| debt to assets | 0.23 | 0.28 | -16.36 |
| net debt to ebitda | -0.37 | 0.65 | -156.53 |
| current ratio | 0.19 | 0.37 | -49.84 |
| interest coverage | -0.88 | -0.95 | 7.29 |
| income quality | 0.76 | 0.72 | 5.10 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.69 | 0.72 | -3.83 |
| research and ddevelopement to revenue | 1.63 | 1.56 | 4.53 |
| intangibles to total assets | 0.12 | 0.1 | 21.62 |
| capex to operating cash flow | -0.01 | -0.01 | 22.92 |
| capex to revenue | 0.02 | 0.02 | 0.72 |
| capex to depreciation | 0.15 | 0.14 | 8.14 |
| stock based compensation to revenue | -0.03 | 0.17 | -116.85 |
| graham number | 16.76 | 25.49 | -34.25 |
| roic | 0.98 | -0.64 | 251.95 |
| return on tangible assets | -0.32 | -0.2 | -57.07 |
| graham net net | -21.59 | -19.79 | -9.11 |
| working capital | -220490000 | -170662000 | -29.20 |
| tangible asset value | -300453000 | -249723000 | -20.31 |
| net current asset value | -460132000 | -413250000 | -11.34 |
| invested capital | -36330000 | 14755000 | -346.22 |
| average receivables | 463000 | 597500 | -22.51 |
| average payables | 48371000 | 50768000 | -4.72 |
| average inventory | 0 | 0.5 | -100.00 |
| days sales outstanding | 0.74 | 2.75 | -73.05 |
| days payables outstanding | 100.26 | 39790.17 | -99.75 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 121.31 | 32.7 | 271.03 |
| payables turnover | 0.9 | 0.0 | 39588.94 |
| inventory turnover | 0 | 0 | NaN |
| roe | 0.76 | 0.22 | 245.60 |
| capex per share | 0.02 | 0.02 | 5.16 |
ROE: Return on Equity (ROE) increased to 0.76 on 2024-09-30 Q3 from 0.22 on 2024-06-30 Q2, representing a change of 245.60%. Suggesting the company has been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.44 on 2024-09-30 Q3 from -1.66 on 2024-06-30 Q2, representing a change of 73.14%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to -0.63 on 2024-09-30 Q3 from -0.34 on 2024-06-30 Q2, representing a change of -88.49%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 0.19 on 2024-09-30 Q3 from 0.37 on 2024-06-30 Q2, representing a change of -49.84%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2025-01-22 14:48:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. Data from five presentations underscore the transformative potential of BOT/BAL across multiple lines of therapy in colorectal cancer, including neoadjuvant, first-line, and refractory settings. Data presented also highlight BOT/BAL'.
Sentiment: Positive
Publish Date: 2025-01-20 13:01:20
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sentiment: Neutral
Publish Date: 2025-01-20 10:40:15
Here is how Agenus (AGEN) and Abbott (ABT) have performed compared to their sector so far this year.
Sentiment: Neutral
Publish Date: 2024-12-18 07:30:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium. The conference will take place on January 23-25, 2025, in San Francisco, California. The presentations will showcase BOT/BAL's activity across three distinct co.
Sentiment: Positive
Publish Date: 2024-12-05 07:30:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiative follows the successful closing of a $22 million mortgage secured by key real estate assets, providing the compan.
Sentiment: Positive
Publish Date: 2024-11-27 08:15:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville, California. Facilitated by L&L Capital, the transaction yields $20 million in net proceeds after closing costs and interest reserve, bolstering the company's cash p.
Sentiment: Negative
Publish Date: 2024-11-22 11:18:00
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Healthcare To Contact Him Directly To Discuss Their Options
Sentiment: Positive
Publish Date: 2024-11-19 10:35:38
Agenus (AGEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Sentiment: Positive
Publish Date: 2024-11-18 10:37:14
The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Sentiment: Positive
Publish Date: 2024-11-15 10:36:10
Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sentiment: Positive
Publish Date: 2024-11-12 10:41:49
Agenus Inc. (NASDAQ:AGEN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Garo Armen - Chairman and CEO Steven O'Day - CMO Robin Taylor - CCO Christine Klaskin - VP of Finance Conference Call Participants Emily Bodnar - H.C. Wainright Madeline Stone - William Blair Operator Good morning and welcome to Agenus' Third Quarter 2024 Conference Call and Webcast.
Sentiment: Negative
Publish Date: 2024-11-12 09:21:11
Agenus (AGEN) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $2.10. This compares to loss of $3.20 per share a year ago.
Sentiment: Negative
Publish Date: 2024-11-05 16:30:00
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110801&wire=1 or contact Joseph E. Levi, Esq.
Sentiment: Negative
Publish Date: 2024-11-05 10:00:00
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110746&wire=1 or contact Joseph E. Levi, Esq.
Sentiment: Negative
Publish Date: 2024-11-05 07:30:00
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110719&wire=1 or contact Joseph E. Levi, Esq.
Sentiment: Negative
Publish Date: 2024-11-05 07:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").
Sentiment: Negative
Publish Date: 2024-11-05 05:45:00
NEW YORK , Nov. 5, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024.
Sentiment: Negative
Publish Date: 2024-11-04 16:20:00
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110658&wire=1 or contact Joseph E. Levi, Esq.
Sentiment: Positive
Publish Date: 2024-11-04 13:50:00
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.
Sentiment: Negative
Publish Date: 2024-11-04 12:30:00
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=110633&wire=1 or contact Joseph E. Levi, Esq.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
